This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lara, P. N. Articles by Gandara, D. R. Search for Related Content PubMed PubMed Citation Articles by Lara, P. N., Jr Articles by Gandara, D. R. Social Bookmarking                            What's this?

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Primo N. Lara, Jr, Mary W. Redman, Karen Kelly, Martin J. Edelman, Stephen K. Williamson, John J. Crowley, David R. Gandara

From the University of California Davis Cancer Center, Sacramento, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; Cancer Research and Biostatistics, Seattle, WA; University of Colorado, Denver, CO; University of Maryland, Baltimore, MD; and the University of Kansas, Kansas City, KS

Corresponding author: Primo N. Lara Jr, MD, University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817; e-mail: primo.lara{at}ucdmc.ucdavis.edu

Purpose Tumor shrinkage categorized as complete response (CR) or partial response (PR) is a fundamental efficacy measure for new cancer treatments and often considered a surrogate for overall survival. However, for any given treatment, many more patients typically achieve stable disease (SD) or have progressive disease (PD) than achieve response. We hypothesized that PD (or its converse, disease control rate [DCR], consisting of CR, PR, SD) is a stronger predictor of survival than response alone in advanced non–small-cell lung cancer (NSCLC), and that this determination might be assessable early on during therapy.

Patients and Methods Data from 984 NSCLC patients entered onto three randomized Southwest Oncology Group trials of platinum-based chemotherapy were pooled and subjected to Landmark survival analysis. Patients were categorized according to proportions alive at weeks 8, 14, and 20 after registration, as well as response status. Elements were fitted into a Cox proportional hazards model.

Results Tumor response (CR, PR) was seen in 260 patients (27%). Median time to response, time to progression, and survival time were 2.0, 4.3 and 8.9 months, respectively. Median survival times among patients with CR/PR, SD, or PD were 13.5, 8.4, and 3.1 months, respectively. Of 892 patients alive at week 8, DCR was 62%. Although CR/PR at week 8 was associated with longer survival (hazard ratio [HR] = 0.61; P < .001), DCR was superior in predicting survival (HR = 0.45; P < .0001).

Conclusion DCR at week 8 is a more powerful predictor of subsequent survival than is the traditional tumor response rate in advanced NSCLC and provides an early assessment of subsequent outcome.

Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. M. Booth, P. Ohorodnyk, and E. A. Eisenhauer Call for Clarity in the Reporting of Benefit Associated With Anticancer Therapies J. Clin. Oncol., November 20, 2009; 27(33): e213 - e214. [Full Text] [PDF]

				T. S.K. Mok, Y.-L. Wu, C.-J. Yu, C. Zhou, Y.-M. Chen, L. Zhang, J. Ignacio, M. Liao, V. Srimuninnimit, M. J. Boyer, et al. Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., October 20, 2009; 27(30): 5080 - 5087. [Abstract] [Full Text] [PDF]

				L. Claret, P. Girard, P. M. Hoff, E. Van Cutsem, K. P. Zuideveld, K. Jorga, J. Fagerberg, and R. Bruno Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics J. Clin. Oncol., September 1, 2009; 27(25): 4103 - 4108. [Abstract] [Full Text] [PDF]

				W. J. Gradishar, D. Krasnojon, S. Cheporov, A. N. Makhson, G. M. Manikhas, A. Clawson, and P. Bhar Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer J. Clin. Oncol., August 1, 2009; 27(22): 3611 - 3619. [Abstract] [Full Text] [PDF]

				W. A. Weber Assessing Tumor Response to Therapy J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S. [Abstract] [Full Text] [PDF]

				F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach Oncologist, May 1, 2009; 14(5): 497 - 510. [Abstract] [Full Text] [PDF]

				W. A. Weber The Use of Positron Emission Tomography versus Computerized Tomography Scans in the Assessment of Response to Therapy ASCO Educational Book, January 1, 2009; 2009(1): 474 - 478. [Abstract] [Full Text] [PDF]

				K. Yonesaka, K. Zejnullahu, N. Lindeman, A. J. Homes, D. M. Jackman, F. Zhao, A. M. Rogers, B. E. Johnson, and P. A. Janne Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers Clin. Cancer Res., November 1, 2008; 14(21): 6963 - 6973. [Abstract] [Full Text] [PDF]

				T. Tanvetyanon, E. A. Eikman, E. Sommers, L. Robinson, D. Boulware, and G. Bepler Computed Tomography Response, But Not Positron Emission Tomography Scan Response, Predicts Survival After Neoadjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer J. Clin. Oncol., October 1, 2008; 26(28): 4610 - 4616. [Abstract] [Full Text] [PDF]

				J. R. Anderson, K. C. Cain, and R. D. Gelber Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables J. Clin. Oncol., August 20, 2008; 26(24): 3913 - 3915. [Full Text] [PDF]

				M. R. Green Lessons From a Time Capsule: Evolution, Not Revolution, in Therapy for Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2008; 26(19): 3112 - 3113. [Full Text] [PDF]

				Xian Zhou, Suyu Liu, E. S Kim, R. S Herbst, and J J. Lee Bayesian adaptive design for targeted therapy development in lung cancer -- a step toward personalized medicine Clinical Trials, June 1, 2008; 5(3): 181 - 193. [Abstract] [PDF]